We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioFocus and Almac Collaborate to Offer Fluorescent Lifetime Assays
News

BioFocus and Almac Collaborate to Offer Fluorescent Lifetime Assays

BioFocus and Almac Collaborate to Offer Fluorescent Lifetime Assays
News

BioFocus and Almac Collaborate to Offer Fluorescent Lifetime Assays

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioFocus and Almac Collaborate to Offer Fluorescent Lifetime Assays"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioFocus and Almac have initiated a collaboration which will provide BioFocus customers with compound screening and profiling services using Almac’s FLEXYTE™ fluorescence lifetime (FLT) assays. FLT as a reading modality offers a robust, antibody free, homogeneous assay platform which enables the user to avoid interference from fluorescent compounds within a screening library.

BioFocus has launched an FLT screening and profiling service utilizing the FLEXYTE™ assay platform and now offer campaigns against targets including proteases, phosphatases and kinases. The unique properties of FLT have also been harnessed to open up access to previously inaccessible epigenetics target classes. Several approaches can be taken using the FLEXYTE™ platform including fragment based screens and kinetic profiling.

‘Being able to incorporate FLT in our service offering enables BioFocus to provide clients an approach to screening and profiling that will unlock significant potential within their drug discovery efforts’ commented Dr Kate Hilyard, VP Biological Sciences, BioFocus.
 
‘We are delighted that BioFocus has chosen to add our FLEXYTE™ platform to their service offering. We feel that this will allow a broad range of drug discovery groups access to the power of FLT’ said Dr Stephen Barr, President and Managing Director of Almac Sciences.

Advertisement